Nothing said here yet.
to join the conversation.
| Williams Amanda MDirector | Buy | 5,857 | $16.0K | Mon, Aug 17 |
| Gould Gregory ACFO | Buy | 10,000 | $24.5K | Fri, Aug 14 |
| Bond RyanDirector | Buy | 21,122 | $50.1K | Thu, Aug 13 |
| Neal David KDirector | Buy | 7,500 | $18.0K | Thu, Aug 13 |
| Ness BrentChief Executive Officer | Buy | 5,234 | $12.1K | Thu, Aug 13 |
| Wesemann WilliamDirector | Buy | 2,150 | $5.0K | Thu, Aug 13 |
Aclarion (ACON) delivered earnings and revenue surprises of -6.67% and -15.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain.
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to…
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to…
Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience groupAdds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic information from SPECT-CT Supports…
Award-winning, NIH funded study indicates that immune-associated biological signatures may play a role in some cases of back painNociscan’s underlying MRS technology enabled measurement of intradiscal propionic acid to uncover immune-linked patient…